The anticipated launch of emerging therapies such as Lisaftoclax, Sonrotoclax, Lacutoclax/LP-108, and others is expected to significantly transform the BCL-2 inhibitors market & drive market expansion through 2036 ... What are BCL-2 Inhibitors?.
BCL’s appointment follows its recent mobilisation to site, marking the transition into the core construction phase of The AutographPlus... The partnership between Cruxstone and BCL represents a strategic alignment of vision and capability.